Thomas E. Timbie - 15 Mar 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Reporting relationship: Director
Issuer ticker: TMCI
Reported as of: 15 Mar 2023
Net transaction value: -$1,151,665
SEC form: 4
Accepted by SEC: 17 Mar 2023, 21:00:07 UTC
Prior SEC filing: 17 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Lisa Taylor as Attorney-in-fact for Thomas Timbie

Key filing fact

Thomas E. Timbie filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 17 Mar 2023.

Key facts

This page summarizes Thomas E. Timbie's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Mar 2023, 21:00.

Change

Previous filing in this sequence was filed on 17 Feb 2023.
Current net transaction value: -$1,151,665.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMCI transaction

Common Stock

Sale

Transaction value: $1,151,665
Shares: -50,000
Change %: -4.2%
Price: $23.03
Shares after: 1,149,069
Date: 15 Mar 2023
Ownership: Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001
Footnotes: F1, F2

TMCI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 361,700
Date: 15 Mar 2023
Ownership: Pamela Timbie and Thomas Timbie as Trustees of the PAMELA F TIMBIE REV TRUST

TMCI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,295
Date: 15 Mar 2023
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Footnote F2

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.7500 to $23.4300 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on May 17, 2023 subject to Reporting Person's providing continued service to Issuer through the vesting date.